'Valeant acquired Cesamet from Eli Lilly in 2004 and already sells the product in Canada, where it has about an 86% share of the cannabinoid market, accoridng to IMS data. It expects to launch Cesamet in the USA within the next few weeks.'
'Nabilone was originally developed by Eli Lilly and Company; Lilly received FDA approval in 1985 to market it, but withdrew that approval in 1989 for commercial reasons.[9] Valeant Pharmaceuticals acquired the rights from Lilly in 2004.[9] Valeant tried and failed to get the drug approved in 2005[10] and then succeeded in 2006.[9]'
What are you basing this on? TDAmeritrade has today's prices at a 7.4 million market cap. Are they wrong, because that would only be around a 122 million market cap at 4.00